

## Product Specification Sheet

**Product Name:** BMS-232632 (Atazanavir)

**Catalog Number:** C2232

### Technical information:

Chemical Formula:  $C_{38}H_{52}N_6O_7$

CAS #: 198904-31-3, 229975-97-7

Molecular Weight: 704.86

Purity: > 99%


Appearance: White solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: 2,5,6,10,13-Pentazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)-

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.142mL of DMSO for each mg of BMS-232632 (Atazanavir)
  - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** Atazanavir (BMS-232632) is an orally available, azapeptide human immunodeficiency virus type 1 (HIV-1) protease inhibitor with EC<sub>50</sub> of 2.6-5.3 nM, and EC<sub>90</sub> of 9-15 nM. [1] Atazanavir has been shown to be effective in HIV-1 strains resistant to other antivirals such as nelfinavir, saquinavir, and amprenavir. Additionally, indinavir- and ritonavir-resistant strains are more six- to nine-fold more sensitive to atazanavir.

Atazanavir's is highly selective for HIV-1 protease and only exhibits cytotoxic effects in 6500- to 23000-fold higher concentrations than is required for anti-HIV activity. Atazanavir has been shown to be additive or synergistic with a number of different antiviral therapies without antagonistic anti-HIV activity or cytotoxicity. [2, 3]

- Reference:**
1. Gong et al., In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. *Antimicrobial Agents Chemother.* 2000, 44(9), 2319-2326. Pubmed ID: 10952574
  2. Robinson et al., BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. *Antimicrobial Agents Chemother.* 2000, 44(8), 2093-2099. Pubmed ID: 10898681
  3. Colonna et al., Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. *Antimicrobial Agents Chemother.* 2003, 47(4), 1324-1333. Pubmed ID: 12654666

To reorder: <http://www.cellagentech.com/BMS-232632-Atazanavir/>

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*